A Phase 2/3 interventional study of Sertraline 50 MG and Allopurinol 300 MG in Depression, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-08-18.
Sponsored by Tanta University · Phase 2/3, Interventional, and Treatment
Major depressive disorder (MDD) is one of the most common psychiatric disorders with serious socioeconomic consequences on daily life and health care costs. Despite the advent of newer antidepressants that target monoamine pathways, nearly 50% of patients have no response to first-line antidepressant therapy. Thus, a combination of medications with different strategies at the beginning of treatment could provide further therapeutic benefits to MDD patients.
8,057 studies on the registry are indexed under Depression; 1,641 are open to participants now.
This study's planned enrollment of 70 is below the median of 84 across 6,720 interventional studies indexed under Depression.
Browse Depression studies →Tanta University is the lead sponsor of 963 studies on the registry; 304 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients aged greater than 18 years old. Patients with a HAM-D score of at least 10 with item 1, depressed mood, scoring 2 or greater, are eligible.
Exclusion Criteria:
Patients with bipolar I or bipolar II disorder Patients with eating disorders Pregnant women or women not using medically accepted means of birth control Cardiovascular disorders Severe renal impairment
35 patients will receive Sertraline 50 mg/day plus a placebo.
Drug: Sertraline 50 MG
35 patients will receive 50 mg/day of sertraline plus allopurinol (300 mg/day).
Drug: Sertraline 50 MG · Drug: Allopurinol 300 MG
Sertraline is an antidepressant medication of the selective serotonin reuptake inhibitor class used to treat major depressive disorder, generalized anxiety disorder, social anxiety disorder, obsessive-compulsive disorder, panic disorder, and premenstrual dysphoric disorder.
Allopurinol is a potent inhibitor of the enzyme xanthine oxidase and is primarily used to treat hyperuricemia and gout
Change in the 17-item Ham-D depression score.
Ham-D depression is a widely used clinician-administered instrument designed to assess the severity of depressive symptoms over the preceding week. It consists of 17 items. Higher scores indicate greater severity of depression, with commonly accepted cutoffs being 0-7 (normal), 8-13 (mild depression), 14-18 (moderate depression), 19-22 (severe depression), and 23 or above (very severe depression).
Time frame: 8 weeks
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Tanta University